SG167667A1 - Nucleic acid compositions for stimulating immune responses - Google Patents

Nucleic acid compositions for stimulating immune responses

Info

Publication number
SG167667A1
SG167667A1 SG200701441-8A SG2007014418A SG167667A1 SG 167667 A1 SG167667 A1 SG 167667A1 SG 2007014418 A SG2007014418 A SG 2007014418A SG 167667 A1 SG167667 A1 SG 167667A1
Authority
SG
Singapore
Prior art keywords
nucleic acid
immune responses
acid compositions
stimulating immune
stimulating
Prior art date
Application number
SG200701441-8A
Inventor
M Krieg Arthur
Original Assignee
Coley Pharm Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Group Inc filed Critical Coley Pharm Group Inc
Publication of SG167667A1 publication Critical patent/SG167667A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
SG200701441-8A 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses SG167667A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39419302P 2002-07-03 2002-07-03
US39409002P 2002-07-03 2002-07-03
US39388002P 2002-07-03 2002-07-03
US39409102P 2002-07-03 2002-07-03
US39416402P 2002-07-03 2002-07-03

Publications (1)

Publication Number Publication Date
SG167667A1 true SG167667A1 (en) 2011-01-28

Family

ID=30119452

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200701441-8A SG167667A1 (en) 2002-07-03 2003-07-03 Nucleic acid compositions for stimulating immune responses

Country Status (7)

Country Link
EP (1) EP1551221A4 (en)
JP (2) JP2005532067A (en)
CN (1) CN1678188B (en)
AU (1) AU2003247880B2 (en)
CA (1) CA2494508A1 (en)
SG (1) SG167667A1 (en)
WO (1) WO2004005476A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572122A4 (en) * 2002-11-01 2008-04-09 Us Gov Health & Human Serv Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
KR101251707B1 (en) * 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
HUE025645T2 (en) * 2007-05-18 2016-04-28 Adiutide Pharmaceuticals Gmbh Phosphate-modified oligonucleotide analogs with immunostimulatory activity
WO2009052376A1 (en) 2007-10-18 2009-04-23 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
JP5589274B2 (en) * 2007-10-25 2014-09-17 東レ株式会社 Immune inducer
JP5359883B2 (en) * 2007-11-28 2013-12-04 東レ株式会社 Hepatitis treatment or prevention
CN101559224B (en) * 2008-04-18 2012-07-11 北京生物制品研究所 Poliomyelitis vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
US20120301498A1 (en) 2011-04-29 2012-11-29 Selecta Biosciences, Inc. Controlled release of immunosuppressants from synthetic nanocarriers
RU2587633C2 (en) * 2011-05-26 2016-06-20 Интервет Интернэшнл Б.В. Immunostimulating oligodeoxynucleotides
CN103547675A (en) 2011-05-26 2014-01-29 英特维特国际股份有限公司 Immunostimulatory oligodeoxynucleotides
BR122020023215B1 (en) 2013-05-03 2022-11-22 Selecta Biosciences, Inc COMPOSITION AND KIT OF TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGEN ANTIGEN
CA2911938C (en) * 2013-05-14 2019-07-16 Zoetis Services Llc Vaccine compositions comprising sp oil and p-class immunostimulatory oligonucleotides
IL292574A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and compositions for attenuating anti-viral transfer vector immune responses
EP3244910B1 (en) * 2015-01-16 2020-09-16 City of Hope Cell penetrating antibodies
NZ750181A (en) * 2016-07-26 2023-02-24 Bayer Animal Health Gmbh Increased fertility in bovine species
JP2020510687A (en) 2017-03-11 2020-04-09 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Methods and compositions relating to combination treatment with synthetic nanocarriers including anti-inflammatory and immunosuppressive agents
CN113440609A (en) * 2020-03-27 2021-09-28 北京市农林科学院 Double-stranded RNA compound AUTP and application thereof in vaccine preparation
CN113493790A (en) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 CpG ODN with immunoregulation function and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
WO2001092565A2 (en) * 2000-04-06 2001-12-06 Epigenomics Ag Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
WO2002018632A2 (en) * 2000-09-01 2002-03-07 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP2002514397A (en) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー Methods for hematopoietic regulation using CpG oligonucleotides
DK1077722T3 (en) * 1998-05-22 2006-11-27 Ottawa Health Research Inst Methods and products for the induction of mucosa immunity
BR0010323A (en) * 1999-05-06 2002-01-08 Immune Response Corp Inc Immunogenic compositions, kit and method of making it for use in the immunization of a mammal
WO2001022990A2 (en) * 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
KR100991644B1 (en) * 2001-08-17 2010-11-02 콜리 파마슈티칼 게엠베하 Combination Motif Immune Stimulatory Oligonucleotides with Improved Activity
AR040996A1 (en) * 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
EP2241325B1 (en) * 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1631687A2 (en) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Methods and products for identification and assessment of tlr ligands

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
WO2001092565A2 (en) * 2000-04-06 2001-12-06 Epigenomics Ag Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
WO2002018632A2 (en) * 2000-09-01 2002-03-07 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'

Also Published As

Publication number Publication date
AU2003247880A1 (en) 2004-01-23
JP2009132737A (en) 2009-06-18
EP1551221A4 (en) 2007-08-01
AU2003247880B2 (en) 2010-09-02
CN1678188B (en) 2012-10-10
CA2494508A1 (en) 2004-01-15
JP2005532067A (en) 2005-10-27
WO2004005476A2 (en) 2004-01-15
EP1551221A2 (en) 2005-07-13
CN1678188A (en) 2005-10-05
WO2004005476A3 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MXPA05002014A (en) Immunostimulatory nucleic acids.
EP1594536A4 (en) Adjuvanted influenza vaccine
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
WO2004030608A3 (en) Nanoemulsion vaccines
MX2009012482A (en) Class a oligonucleotides with immunostimulatory potency.
HK1034039A1 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
TNSN07150A1 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2004053104A3 (en) 5’ cpg nucleic acids and methods of use
MY125202A (en) Vaccine
MXPA05013973A (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes.
IL175512A0 (en) Methods of preparing aripiprazole crystalline forms
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
AU2002242085A1 (en) Methods and compositions useful for stimulating an immune response
MXPA05008360A (en) Short immunomodulatory oligonucleotides.
DK0876398T3 (en) Induction of immune response with desired determinants
TNSN05052A1 (en) Immunostimulatory nucleic acids
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
EP1689430A4 (en) Tyrosinase mutant and methods of use thereof